FATE
Fate Therapeutics Inc

6,315
Mkt Cap
$125.73M
Volume
1.01M
52W High
$2.07
52W Low
$0.661
PE Ratio
-0.84
FATE Fundamentals
Price
$1.11
Prev Close
$1.09
Open
$1.09
50D MA
$1.24
Beta
1.14
Avg. Volume
1.59M
EPS (Annual)
-$1.64
P/B
0.55
Rev/Employee
$75,309.39
Loading...
Loading...
News
all
press releases
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Below 200 Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Below 200 Day Moving Average - What's Next...
MarketBeat·14d ago
News Placeholder
More News
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been assigned a consensus rating of "Hold" from the nine brokerages that are presently covering the firm, Marketbeat.com...
MarketBeat·24d ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts...
MarketBeat·27d ago
News Placeholder
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +6.90% and +104.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Zacks·1mo ago
News Placeholder
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest FATE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.